Loading
A phase 2 trial of Prednisone, Abiraterone acetate in prostate cancer, run by Astellas Pharma Global Development, Inc., now recruiting.
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer is a phase 2 interventional study registered as NCT07005154 by Astellas Pharma Global Development, Inc., with 218 participants planned, started 2025-08-19 and due to reach its primary completion in 2032-05-31. Interventions recorded: ASP5541, Prednisone, Prednisolone, abiraterone acetate, Adrenocorticotropic hormone. Conditions listed: Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer. No results are recorded here; the registry entry is the source.
Shares Abiraterone acetate, Prednisone, Prostate cancer.
Shares Astellas, Abiraterone acetate, Prednisone, Prostate cancer.
Shares Abiraterone acetate, Prednisone, Prostate cancer.
Shares Abiraterone acetate, Prednisone, Prostate cancer.
Shares Abiraterone acetate, Prednisone, Prostate cancer.
Shares Abiraterone acetate, Prednisone, Prostate cancer.
Shares Abiraterone acetate, Prostate cancer.
Shares Prednisone, Prostate cancer.